INSPINSP
US • —
$44.61
P/E
9.96
PEG
0.09
FCF Yield
—
Rev Growth YoY
+8.9% YoY
Gross Margin
85.8%
Health Score
7/10
D/E Ratio
—
Confidence
MEDIUM
Business Snapshot
Inspire Medical Systems, Inc. (INSP) is a medical technology company focused on developing and commercializing innovative solutions for patients with obstructive sleep apnea. The company operates in the fast-growing sleep-disordered breathing market, where it positions itself as a niche leader with an advanced neurostimulation therapy platform. Inspire's defining characteristic is its proprietary hypoglossal nerve stimulation technology, which offers an alternative to traditional positive airway pressure (PAP) therapy for patients who cannot tolerate CPAP machines.
Financial Health
Gross margin stands at a robust 85.8%, reflecting strong pricing power and a high-value product mix, while the net margin of 14.3% indicates solid profitability. The balance sheet is exceptionally conservative, with a debt-to-equity ratio of 0.0x and a current ratio of 6.08x, signalling a fortress-like liquidity position with no financial leverage...
Risk Assessment
- INSIDER SELLING — Insiders have executed 3 sells versus 0 buys in the last 90 days, a net sell signal that warrants monitoring.
- ANALYST SENTIMENT — Only 33% of analysts rate the stock a buy, with 62% on hold, indicating limited Wall Street endorsement.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- EARNINGS CREDIBILITY — While 3 of the last 4 quarters beat estimates, the single miss represents a minor inconsistency in management's track record....
Gross margin stands at a robust 85.8%, reflecting strong pricing power and a high-value product mix, while the net margin of 14.3% indicates solid profitability. The balance sheet is exceptionally conservative, with a debt-to-equity ratio of 0.0x and a current ratio of 6.08x, signalling a fortress-like liquidity position with no financial leverage. Free cash flow data is not available, preventing a full assessment of cash generation versus reported earnings. Overall, the company operates from a position of significant financial strength, with ample liquidity to fund R&D and potential growth initiatives without reliance on external financing.
- INSIDER SELLING — Insiders have executed 3 sells versus 0 buys in the last 90 days, a net sell signal that warrants monitoring. - ANALYST SENTIMENT — Only 33% of analysts rate the stock a buy, with 62% on hold, indicating limited Wall Street endorsement. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - EARNINGS CREDIBILITY — While 3 of the last 4 quarters beat estimates, the single miss represents a minor inconsistency in management's track record.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives